Late Breaking Abstract: A randomised, placebo controlled trial of 6 weeks‘ treatment with a novel oral p38 inhibitor in patients with COPD
W. MacNee, R. Allan, I. Jones, M. C. De Salvo, L. Tan (Edinburgh, Sandwich, United Kingdom; Buenos Aires, Argentina)
Source: Annual Congress 2010 - COPD: management
Session: COPD: management
Session type: Thematic Poster Session
Number: 4000
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. MacNee, R. Allan, I. Jones, M. C. De Salvo, L. Tan (Edinburgh, Sandwich, United Kingdom; Buenos Aires, Argentina). Late Breaking Abstract: A randomised, placebo controlled trial of 6 weeks‘ treatment with a novel oral p38 inhibitor in patients with COPD. Eur Respir J 2010; 36: Suppl. 54, 4000
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021
Late Breaking Abstract: High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis: A double-blind randomised controlled trial Source: Annual Congress 2010 - Clinical tuberculosis Year: 2010
Supplementation of N-acetylcysteine as an adjuvant in treatment of newly diagnosed pulmonary tuberculosis patients: A prospective, randomized double blind, placebo controlled study Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019
RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022
Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial Source: Annual Congress 2010 - COPD exacerbation Year: 2010
Late Breaking Abstract - Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers: a randomised, placebo controlled, cross-over study Source: Eur Respir J 2003; 22: Suppl. 45, 49s Year: 2003
Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020
Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial Source: International Congress 2016 – Asthma management Year: 2016
Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018
Multidimensional assessment and targeted therapy of severe asthma: a randomised controlled trial (RCT) Source: International Congress 2017 – Many faces of asthma assessment Year: 2017
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021